Melanoma Diagnostics Leader, MELA Sciences, Hosts Clinical Advisory Meeting Friday, Dec. 6th in Conjunction with Mount Sinai ...
December 05 2013 - 7:56AM
Business Wire
MELA Sciences, Inc. (NASDAQ:MELA) designer and developer of
MelaFind®, an FDA approved non-invasive optical device that assists
dermatologists in diagnosing melanoma at its most curable stage,
announces the Company will participate in the 16th Annual Mount
Sinai Winter Dermatology Symposium in New York City, December 6-8,
2013. In conjunction with the Symposium, MELA will also host its
second Clinical Advisory Meeting on Friday, December 6, 2013.
The Mount Sinai Symposium focuses on the most current research,
devices, surgical techniques, cosmetic agents and diagnosis and
treatment techniques for a variety of skin conditions, including
skin cancer. The symposium is intended for dermatologists, cosmetic
surgeons, physician assistants, nurse practitioners, residents,
fellows, medical students and allied health professionals.
MELA Sciences Clinical Advisory Meeting – Winter 2013
The Clinical Advisory Meeting will gather thought leaders in the
field of medical dermatology to discuss the use, clinical value and
future potential of MelaFind®, MELA Sciences’ optical imaging
technology. Gary Goldenberg, MD, Assistant Professor, Dermatology
and Pathology, and Medical Director of the Dermatology Faculty
Practice at Mount Sinai’s Department of Dermatology will chair the
meeting. Dr. Goldenberg has been using the Company’s MelaFind®
optical diagnostic device in clinical practice for over a year.
Dr. Goldenberg, commented, “MELA Sciences is a true pioneer in
bringing innovative optical imaging technology to the challenging
process of melanoma diagnosis. MelaFind® data and images literally
provide dermatologists with ‘another set of eyes’ to help them in
their assessment of pigmented skin lesions for possible melanoma.
Like other imaging technologies, there seems to be much additional
potential for their technology to aid in the diagnosis of skin
disorders.”
MELA Sciences will share new insights and data on the MelaFind®
system’s performance and clinical applications, as well as possible
new applications being researched at leading centers in the U.S.
and Germany. The Company seeks to position MelaFind® and its unique
optical imaging technology and data analysis as a standard of care
in computer assisted mole monitoring and management of ambiguous
pigmented skin lesions.
Julie E. Russak, M.D., FAAD, a specialist in skin cancer and
melanoma, will keynote the session discussing how MelaFind® has
aided her biopsy decision making process during melanoma
examinations as well as in her ability to communicate with patients
about the state of their skin lesions. Dr. Russak will also speak
about how she has integrated the quick, painless MelaFind®
evaluation into the workflow at Russak Dermatology Clinic, her
thriving midtown Manhattan dermatology practice. Dr. Russak is a
Board Certified Dermatologist, a Fellow of the American Academy of
Dermatology, a member of the American Society of Dermatologic
Surgery, and a Volunteer Faculty in Dermatology at Mount Sinai
Hospital. In addition to extensive research in Cutaneous Oncology,
Dr. Russak has published multiple journal articles and authored a
chapter for a prominent skin cancer textbook. She was also the
editor of the July 2012 issue of the Dermatologic Clinic’s update
on Melanoma and Pigmented Lesions.
Rose Crane, CEO of MELA Sciences, commented, “Having recently
reoriented our MelaFind® marketing strategy to focus on opinion
leaders in medical dermatology, the Mount Sinai Symposium provides
an excellent opportunity to introduce and expand awareness of our
technology and to gather feedback from some of the nation’s leading
physicians. We are grateful for the support we have received from
Mount Sinai and our presenting physicians and look forward to
expanding awareness of our technology which can assist
dermatologists in the fight against melanoma.”
Melanoma – Deadly but Curable if Caught Early
Melanoma is a skin cancer formed in melanocytes, cells
responsible for forming pigments (melanin) responsible for skin
color. Melanoma is the deadliest and fastest growing cancer in the
U.S., according to the Skin Cancer Foundation. Doctors in the
United States diagnose about 160,000 new cases of melanoma per
year, and the World Health Organization estimates about 48,000
melanoma related deaths occur worldwide each year. Melanoma is
almost 100% curable if caught early; however, according to
according to a Harris Interactive Study commissioned by MELA
Sciences, 76% of Americans have never had a skin check by a
dermatologist.
About MELA Sciences, Inc. www.melasciences.com
MELA Sciences is a medical device company developing dermatology
diagnostics utilizing state-of-the-art optical imaging. The
Company’s flagship product is MelaFind®, an FDA approved,
non-invasive diagnostic tool to aid dermatologists in melanoma
evaluation and diagnosis. MelaFind® uses a variety of visible to
near-infrared light waves to evaluate skin lesions from the surface
to 2.5 mm beneath the skin. The device provides images and data on
the relative disorganization of a lesion's cell structure that
provides substantial additional perspective to aid in melanoma
diagnosis. MELA is also exploring new potential uses for its core
imaging technology and algorithms. MelaFind® has also received CE
Mark approval and is approved for use in the European Union.
Safe Harbor
This press release includes "forward-looking statements" within
the meaning of the Securities Litigation Reform Act of 1995. These
statements include but are not limited to our plans, objectives,
expectations and intentions and may contain words such as “seeks,”
“look forward,” and “there seems” that suggest future events or
trends. These statements are based on our current expectations and
are inherently subject to significant uncertainties and changes in
circumstances. Actual results may differ materially from our
expectations due to financial, economic, business, competitive,
market, regulatory and political factors or conditions affecting
the company and the medical device industry in general, as well as
more specific risks and uncertainties set forth in the company’s
SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any
or all of these forward-looking statements may prove to be
incorrect or unreliable. MELA Sciences assumes no duty to update
its forward-looking statements and urges investors to carefully
review its SEC disclosures available at www.sec.gov and
www.melasciences.com.
InvestorsCatalyst Global LLCToni Trigiani, David
Collins212-924-9800mela@catalyst-ir.comorMediaRpr Marketing
CommunicationsErica Sperling,
212-317-1462Erica.Sperling@rprmc.com
Strata Skin Sciences (NASDAQ:SSKN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Strata Skin Sciences (NASDAQ:SSKN)
Historical Stock Chart
From Sep 2023 to Sep 2024